The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients

Clinical Pharmacokinetics

Volumn 50, Issue 2, 2011, Pages 99-110

  Ulldemolins, Marta ^a,b,c   Roberts, Jason A ^a,d   Rello, Jordi ^b,c,e   Paterson, David L ^d,f   Lipman, Jeffrey ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; CARBAPENEM; CEFALOTIN; CEFTRIAXONE; DALBAVANCIN; DAPTOMYCIN; ERTAPENEM; FLUCLOXACILLIN; FROPENEM; FUSIDIC ACID; GLYCOPEPTIDE; ICLAPRIM; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ALBUMIN BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BURN; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HYPOALBUMINEMIA; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; DRUG DOSAGE CALCULATIONS; HUMANS; HYPOALBUMINEMIA; KIDNEY FUNCTION TESTS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING;

EID: 78751558968     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11539220-000000000-00000     Document Type: Review

References (63)

1. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokine- tics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45 (8): 755-73.
2. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37 (3): 840-51.
3. Craig WA, Suh B. Changes in protein binding during disease. Scand J Infect Dis Suppl 1978; (14): 239-44.
4. Suh B, Craig WA, England AC, et al. Effect of free fatty acids on protein binding of antimicrobial agents. J Infect Dis 1981; 143 (4): 609-16.
5. Friend R, Hatchett L, Wadhwa NK, et al. Serum albumin and depression in end-stage renal disease. Adv Perit Dial 1997; 13: 155-7.
6. Novak M, Polacek K, Melichar V. Competition between bilirubin and non- esterified fatty acids for binding to albumin. Biol Neonat 1962; 4: 310-5.
7. Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin con- centration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the Saline versus Albumin Fluid Evaluation (SAFE) study. BMJ 2006; 333 (7577): 1044.
8. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983; 11 (3): 233-8.
9. LiuP, DerendorfH. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003; 17 (3): 599-613.
10. Goldstein A. The interactions of drugs and plasma proteins. J Pharmacol Exp Ther 1949; 95 Pt. 2 (4): 102-65.
11. Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacokinet 1978; 3 (2): 144-54.
12. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet 1985; 1 (8432): 781-4.
13. Jarnum S. Turnover of plasma proteins. J Clin Pathol Suppl (Assoc Clin Pa- thol) 1975; 6: 13-21.
14. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389: 39-48.
15. Kirsch R, Frith L, Black E, et al. Regulation of albumin synthesis and cata- bolism by alteration of dietary protein. Nature 1968; 217 (5128): 578-9.
16. Heyland DK, Tougas G, King D, et al. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996; 22 (12): 1339-44.
17. Cooper JK, Gardner C. Effect of aging on serum albumin. J Am Geriatr Soc 1989; 37 (11): 1039-42.
18. Mariani G, Strober W, Keiser H, et al. Pathophysiology of hypoalbuminemia associated with carcinoid tumor. Cancer 1976; 38 (2): 854-60.
19. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59 (2): 277-84.
20. Joynt GM, Lipman J,Gomersall CD, etal. The pharmacokineticsofonce-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47 (4): 421-9.
21. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994; 105 (2): 602-4.
22. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial in- vestigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156 (1): 196-200.
23. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before in- itiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34 (6): 1589-96.
24. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibiotic dosing in the critically ill. Clin Pharmacokinet 2009; 49 (1): 1-16.
25. Mimoz O, Soreda S, Padoin C, et al. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs. Anesthesiology 2000; 93 (3): 735-43.
26. Donnelly AJ, Baughman VL, Gonzales JP, et al. Anesthesiology & critical care drug handbook. 8th ed. Hudson (OH): Lexi-Comp, 2008.
27. MIMS Australia [online]. Available from URL: http://www.mims.com.au/ [Accessed 2009 Dec].
28. Dalley AJ, Deans R, Lipman J, et al. Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury. Antimicrob Agents Chemother 2009; 53 (12): 5303-5.
29. Ulldemolins M, Roberts J, Wallis S, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminemia: special emphasis on unbound pharmaco-kinetics. J Antimicrob Chemother 2010; 65 (8): 1771-8.
30. Boselli E, Breilh D, Saux MC, et al. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006; 32 (12): 2059-62.
31. Brink AJ, Richards GA, Schillack V, et al. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Anti-microb Agents 2009; 33 (5): 432-6.
32. Seguin P, Verdier MC, Chanavaz C, et al. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. J Antimicrob Chemother 2009; 63 (3): 564-7.
33. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemo-ther 2009; 53 (2): 428-34.
34. Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med 2006; 32 (5): 775-9.
35. Swabb EA, Leitz MA, Pilkiewicz FG, et al. Pharmacokinetics of the mono- bactam SQ 26,776 after single intravenous doses in healthy subjects. J Anti-microb Chemother 1981; 8 Suppl. E: 131-40.
36. Janicke DM, Cafarell RF, Parker SW, et al. Pharmacokinetics of aztreonam in patients with Gram-negative infections. Antimicrob Agents Chemother 1985; 27 (1): 16-20.
37. Friedrich LV, White RL, Kays MB,et al. Aztreonam pharmacokinetics inburn patients. Antimicrob Agents Chemother 1991; 35 (1): 57-61.
38. StoeckelK, McNamara PJ, Brandt R, et al. Effectsofconcentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 1981; 29 (5): 650-7.
39. Van Dalen R, Vree TB, Baars IM. Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharm Weekbl Sci 1987; 9 (2): 98-103.
40. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flu-cloxacillin. Antimicrob Agents Chemother 2007; 51 (9): 3290-7.
41. Pletz MW, Rau M, Bulitta J, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48 (10): 3765-72.
42. Outman WR, Nightingale CH, Sweeney KR, et al. Teicoplanin pharmaco- kinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother 1990; 34 (11): 2114-7.
43. Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and pharmaco- dynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003; 29 (9): 1528-34.
44. Healy DP, Polk RE, Garson ML, et al. Comparison of steady-state pharm- acokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987 Mar; 31 (3): 393-7.
45. Fernandez de Gatta Garcia M, Revilla N, Calvo MV, et al. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33 (2): 279-85.
46. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47 (4): 1318-23.
47. Mohr 3rd JF, Ostrosky-Zeichner L, Wainright DJ, et al. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 2008; 52 (5): 1891-3.
48. Taburet AM, Guibert J, Kitzis MD, et al. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J Antimicrob Chemother 1990; 25 Suppl. B: 23-31.
49. Peter JD, Jehl F, Pottecher T, et al. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob Agents Chemother 1993; 37 (3): 501-6.
50. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for an- tibacterial dosing of mice and men. Clin Infect Dis 1998; 26 (1): 1-10.
51. Perry TR, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic-phar- macodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet 2001; 40 (9): 685-94.
52. Jungbluth GL, Pasko MT, Beam TR, et al. Ceftriaxone disposition in open- heart surgery patients. Antimicrob Agents Chemother 1989; 33 (6): 850-6.
53. Bonate PL. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 1990; 18 (2): 118-30.
54. Brogard JM, Haegele P, Kohler JJ, et al. The biliary excretion of cephalothin. Chemotherapy 1973; 18 (4): 212-21.
55. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev 2004; 2 (4): 289-300.
56. Leroy A, Fillastre JP, Borsa-Lebas F, et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992; 36 (12): 2794-8.
57. INVANZ® [ertapenem for injection]: US prescribing information. Whitehouse Station (NJ): Merck Sharp & Dohme Corp., 2010 Mar [online]. Available from URL: http://www.merck.com/product/usa/pi-circulars/i/invanz/ invanz- pi.pdf [Accessed 2010 Nov 16].
58. Boswell FJ, Ashby JP, Andrews JM, et al. Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. J Antimicrob Chemother 2002; 50 (4): 525-32.
59. Soy D, Lopez E, Ribas J. Teicoplanin population pharmacokinetic analysis in hospitalized patients. Ther Drug Monit 2006; 28 (6): 737-43.
60. Godtfredsen WO, Vangedal S. On the metabolism of fusidic acid in man. Acta Chem Scand 1966; 20 (6): 1599-607.
61. Targocid (teicoplanin): Australian product information. Macquarie (NSW): Sanofi-Aventis Australia Pty Ltd, 2009 Jul 6 [online]. Available from URL: http://www.sanofi-aventis.com.au/products/aus-pi-targocid.pdf [Accessed 2010 Nov 12].
62. Brink AJ, Richards GA, Cummins RR, et al. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008; 32 (5): 455-8.
63. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998; 20 (5): 473-7